Inovio Pharma (NASDAQ: INO) reported Q4 EPS of ($0.34), $0.06 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $2.5 million versus the consensus estimate of $2.39 million.

For earnings history and earnings-related data on Inovio Pharma (INO) click here.